Abstract: An organic light emitting diode (OLED) includes a first emitting material layer disposed adjacently to a first electrode and a second emitting material layer disposed adjacently to a second electrode. The first emitting material layer includes a first compound having high affinity to holes and a second compound of thermally activated delayed fluorescent material, and the second emitting material layer includes a fourth compound having high affinity to electrons and implementing triplet-triplet annihilation. Two emitting material layers having adjusted energy levels allow the OLED to lower its driving voltages and improve its luminous efficiency and luminous lifetime.

Abstract: In one example, a semiconductor device can comprise a substrate, a device stack, first and second internal interconnects, and an encapsulant. The substrate can comprise a first and second substrate sides opposite each other, a substrate outer sidewall between the first substrate side and the second substrate side, and a substrate inner sidewall defining a cavity between the first substrate side and the second substrate side. The device stack can be in the cavity and can comprise a first electronic device, and a second electronic device stacked on the first electronic device. The first internal interconnect can be coupled to the substrate and the device stack. The encapsulant can cover the substrate inner sidewall and the device stack and can fill the cavity. Other examples and related methods are disclosed herein.

Abstract: The present disclosure provides an organic light emitting diode including a first electrode; a second electrode facing the first electrode; and an emitting material layer including a first compound and a second compound positioned between the first and second electrodes, wherein the first compound includes a hexagonal-ring moiety including one boron atom, one oxygen atom and four carbon atoms, and the second compound includes a hexagonal-ring moiety including one boron atom, one nitrogen atom and four carbon atoms, and an organic light emitting device including the organic light emitting diode.

Abstract: An array substrate for a narrow bezel type liquid crystal display device and method of manufacturing the same are provided. The array substrate includes: gate lines (GLs) on a substrate, the substrate including a display area and first to fourth non-display areas at respective sides, pixel regions, a gate insulating layer (GIL) on the GLs, a plurality of data lines on the GIL and crossing the GLs, a plurality of gate auxiliary lines parallel to the data lines and connected to respective GLs, an auxiliary line in the third non-display area with a first layer under the GIL and a second layer on the GIL, the first layer contacting the second layer through a first auxiliary contact hole in the GIL, a thin film transistor in each pixel region and connected to the GLs and data lines, and a pixel electrode connected to each thin film transistor.

Abstract: An array substrate for a narrow bezel type liquid crystal display device and method of manufacturing the same are provided. The array substrate includes: gate lines (GLs) on a substrate, the substrate including a display area and first to fourth non-display areas at respective sides, pixel regions, a gate insulating layer (GIL) on the GLs, a plurality of data lines on the GIL and crossing the GLs, a plurality of gate auxiliary lines parallel to the data lines and connected to respective GLs, an auxiliary line in the third non-display area with a first layer under the GIL and a second layer on the GIL, the first layer contacting the second layer through a first auxiliary contact hole in the GIL, a thin film transistor in each pixel region and connected to the GLs and data lines, and a pixel electrode connected to each thin film transistor.

Abstract: The present invention provides an elastase-inhibiting protein isolated ("Guamerin") from a Korean leech, Guameri (Hirudo nipponia) and a process for preparing the same. Guamerin is a protein of a molecular weight of 6,110 Da which is composed of 57 amino acid residues, whose active site is composed of 36-methionine and 37-isoleucine, which retains an inhibiting-activity highly specific to elastase, and which shows stability against heat as well as strong acids and alkalies. Guamerin of the present invention can be applied in the treatment of diseases associated with an excess level of elastase, such as rheumatoid arthritis, emphysema, and psoriasis.